文献速递心脑血管急症重症综合管理与镇静镇痛

挥发性麻醉药与全凭静脉麻醉在心脏手术中的比较

Volatile Anesthetics versus Total Intravenous Anesthesia for Cardiac Surgery.
PubMed 文献 · N Engl J Med · 2019-03-19
一句话结论择期CABG患者中,挥发性麻醉药与全凭静脉麻醉相比1年全因死亡无显著差异(2.8% vs 3.0%,RR 0.94,95%CI 0.69–1.29,P=0.71),试验因无效提前终止。

该研究为在13个国家36个中心进行的实用性、多中心、单盲、对照试验,纳入择期CABG患者,随机分为术中挥发性麻醉药(地氟烷、异氟烷或七氟烷)组或全凭静脉麻醉组,主要终点为1年全因死亡。共随机分配5400例患者(挥发性麻醉药组2709例,全凭静脉麻醉组2691例),64%患者行体外循环下CABG,平均体外循环时间79分钟。第二次中期分析时,数据与安全监察委员会建议因无效提前终止试验。1年全因死亡在挥发性麻醉药组为2.8%,全凭静脉麻醉组为3.0%,相对风险0.94(95%CI 0.69–1.29,P=0.71),数据可获取5353例(99.1%);30天死亡分别为1.4%和1.3%,相对风险1.11(95%CI 0.70–1.76),数据可获取5398例(99.9%)。两组任何次要结局及预设不良事件(包括心肌梗死)发生率均无显著差异。结论:择期CABG患者中,挥发性麻醉药麻醉并未较全凭静脉麻醉显著减少1年死亡。

要点

  • 择期CABG患者中,挥发性麻醉药组1年全因死亡2.8%,全凭静脉麻醉组3.0%,RR 0.94(95%CI 0.69–1.29,P=0.71),无显著差异。
  • 30天全因死亡挥发性麻醉药组1.4%,全凭静脉麻醉组1.3%,RR 1.11(95%CI 0.70–1.76),无显著差异。
  • 两组任何次要结局及预设不良事件(包括心肌梗死)发生率均无显著差异。
  • 试验在第二次中期分析时因无效被数据与安全监察委员会建议提前终止。
  • 64%患者行体外循环下CABG,平均体外循环时间79分钟。

适用人群与场景

  • 择期行冠状动脉旁路移植术(CABG)的患者,来自13个国家36个中心。

处置流程与药物剂量

  • 术中麻醉方案随机分配为含挥发性麻醉药(地氟烷、异氟烷或七氟烷)或全凭静脉麻醉。

研究设计与关键结果

  • 研究类型:实用性、多中心、单盲、对照试验;样本量5400例(挥发性麻醉药组2709例,全凭静脉麻醉组2691例);13个国家36个中心;人群为择期CABG患者;干预为术中挥发性麻醉药(地氟烷、异氟烷或七氟烷),对照为全凭静脉麻醉。
  • 主要终点:1年全因死亡挥发性麻醉药组2.8% vs 全凭静脉麻醉组3.0%,相对风险0.94(95%CI 0.69–1.29,P=0.71),数据可获取5353例(99.1%)。
  • 关键次要终点:30天全因死亡挥发性麻醉药组1.4% vs 全凭静脉麻醉组1.3%,相对风险1.11(95%CI 0.70–1.76),数据可获取5398例(99.9%)。
  • 两组任何次要结局及预设不良事件(包括心肌梗死)发生率均无显著差异。
  • 第二次中期分析时数据与安全监察委员会建议因无效提前终止试验。
  • 64%患者行体外循环下CABG,平均体外循环时间79分钟。

证据类型、等级与局限

  • 证据类型:实用性、多中心、单盲、随机对照试验。
  • 局限:试验在第二次中期分析时因无效被数据与安全监察委员会建议提前终止。

对床旁实践的改变

  • 择期CABG患者中,术中挥发性麻醉药(地氟烷、异氟烷或七氟烷)与全凭静脉麻醉相比1年全因死亡无显著差异,不改变现有麻醉选择依据。
  • 两组30天死亡、次要结局及预设不良事件(包括心肌梗死)发生率均无显著差异。

指南或共识出处

  • MYRIAD试验(ClinicalTrials.gov编号NCT02105610),由意大利卫生部资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Volatile (inhaled) anesthetic agents have cardioprotective effects, which might improve clinical outcomes in patients undergoing coronary-artery bypass grafting (CABG).

METHODS: We conducted a pragmatic, multicenter, single-blind, controlled trial at 36 centers in 13 countries. Patients scheduled to undergo elective CABG were randomly assigned to an intraoperative anesthetic regimen that included a volatile anesthetic (desflurane, isoflurane, or sevoflurane) or to total intravenous anesthesia. The primary outcome was death from any cause at 1 year.

RESULTS: A total of 5400 patients were randomly assigned: 2709 to the volatile anesthetics group and 2691 to the total intravenous anesthesia group. On-pump CABG was performed in 64% of patients, with a mean duration of cardiopulmonary bypass of 79 minutes. The two groups were similar with respect to demographic and clinical characteristics at baseline, the duration of cardiopulmonary bypass, and the number of grafts. At the time of the second interim analysis, the data and safety monitoring board advised that the trial should be stopped for futility. No significant difference between the groups with respect to deaths from any cause was seen at 1 year (2.8% in the volatile anesthetics group and 3.0% in the total intravenous anesthesia group; relative risk, 0.94; 95% confidence interval [CI], 0.69 to 1.29; P = 0.71), with data available for 5353 patients (99.1%), or at 30 days (1.4% and 1.3%, respectively; relative risk, 1.11; 95% CI, 0.70 to 1.76), with data available for 5398 patients (99.9%). There were no significant differences between the groups in any of the secondary outcomes or in the incidence of prespecified adverse events, including myocardial infarction.

CONCLUSIONS: Among patients undergoing elective CABG, anesthesia with a volatile agent did not result in significantly fewer deaths at 1 year than total intravenous anesthesia. (Funded by the Italian Ministry of Health; MYRIAD ClinicalTrials.gov number, NCT02105610.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Landoni G, Lomivorotov VV, Nigro Neto C, et al. Volatile Anesthetics versus Total Intravenous Anesthesia for Cardiac Surgery. N Engl J Med. 2019. PMID: 30888743. doi:10.1056/NEJMoa1816476

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。